Genentech/Roche Deal History & Licensing Activity
Genentech/Roche is a life sciences. Over the past three years, Genentech/Roche has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals). The company currently has 19 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
1
Active Trials
19
Top Modality
Antibodies
Focus Area
Hematological Malignancies
Genentech/Roche Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genentech/Roche in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| XmAb24306 (IL-15 cytokine therapeutic) | Xencor | Antibodies | Unknown | co development | Jul 10, 2026 |
Genentech/Roche Pipeline Focus
Therapeutic areas and modalities where Genentech/Roche is most active based on deal history and clinical trial data.
Therapeutic Areas
Genentech/Roche Clinical Pipeline
Genentech/Roche has 19 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
2
Unknown
7
Phase 1
3
Phase 2
5
Phase 3
See How Your Asset Matches Genentech/Roche's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Genentech/Roche Licensing & Deal Activity
Genentech/Roche is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Genentech/Roche ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genentech/Roche include Hematological Malignancies (8 deals and trials), Solid Tumors (4 deals and trials), CNS Disorders (3 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, Genentech/Roche has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genentech/Roche and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Genentech/Roche's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.